Skip to main content
三元基因 logo

三元基因 — Investor Relations & Filings

Ticker · 920344 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2025-08-21 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920344

About 三元基因

http://www.triprime.com/

Beijing Tri-Prime Gene Pharmaceutical Co., Ltd. is a biotechnology enterprise specializing in the research, development, production, and commercialization of modern genetic engineering pharmaceuticals. The company's core focus is on recombinant human interferon products, most notably Interferon ̑1b. This product is widely utilized in the treatment of viral diseases and malignant tumors, with a significant presence in the pediatric respiratory and hepatology markets. Tri-Prime Gene leverages advanced molecular biology and protein purification technologies to maintain its position as a leader in the interferon market. Its portfolio includes various formulations such as injections, sprays, and drops, designed to meet diverse clinical needs. The company continues to invest in innovative biopharmaceuticals, aiming to provide effective therapeutic solutions for infectious diseases and oncology.

Recent filings

Filing Released Lang Actions
董事、高级管理人员持股变动管理制度
Board/Management Information Classification · 95% confidence The document is titled '董事、高级管理人员持股变动管理制度' which translates to 'Management System for Shareholding Changes of Directors and Senior Management'. It details rules and procedures regarding shareholding changes, reporting, disclosure, and restrictions for directors and senior management. It includes sections on legal compliance, reporting obligations, prohibited periods for trading, and penalties for violations. The document is a formal policy or governance document approved by the board on a specific date (August 20, 2025). It does not contain financial statements, earnings data, or audit information. It is not an announcement of a report but a detailed internal governance policy related to management shareholding. Therefore, it fits best under Board/Management Information (MANG) as it concerns management shareholding rules and internal governance related to directors and senior management.
2025-08-21 Chinese
信息披露管理制度
Governance Information Classification · 95% confidence The document is titled "北京三元基因药业股份有限公司 信息披露管理制度" which translates to "Beijing Sanyuan Gene Pharmaceutical Co., Ltd. Information Disclosure Management System." The content extensively details the company's policies, procedures, and rules regarding information disclosure, including principles, responsibilities, reporting requirements, and internal controls. It references regulatory frameworks such as the Securities Law, Stock Exchange rules, and audit requirements. The document is a comprehensive governance and compliance manual related to information disclosure management rather than a financial report, earnings release, or announcement of voting results. It does not contain financial statements or earnings data, nor is it a transcript or presentation. It is a governance-related document outlining internal rules and practices for disclosure. Therefore, the most appropriate classification is Governance Information (CGR). The document length (15,000 characters) and detailed content support this classification with high confidence.
2025-08-21 Chinese
总经理工作细则
Board/Management Information Classification · 95% confidence The document is titled '总经理工作细则' which translates to 'General Manager Work Rules' or 'General Manager Operating Procedures'. It details the responsibilities, authority, meeting procedures, and reporting obligations of the General Manager within the company. The document includes references to the company's governance structure, board meetings, and internal management rules. There is no financial data, no audit information, no voting results, no earnings or capital updates, and no mention of shareholder meetings or regulatory filings. The content is focused on internal management and governance practices related to the General Manager's role. Therefore, this document fits best under 'Board/Management Information (MANG)' as it announces or details management roles and internal governance related to senior management.
2025-08-21 Chinese
内部控制制度
Governance Information Classification · 95% confidence The document is titled '内部控制制度' (Internal Control System) and is issued by the company's board of directors. It details the internal control policies, responsibilities, and evaluation procedures within the company. The document includes references to the board's approval, internal audit functions, risk management, and control activities. It is a comprehensive governance-related document focusing on internal control frameworks and procedures rather than financial results or announcements. There is no indication that this is an announcement of a report publication or a brief notice. The content aligns with governance practices and internal control systems, which fall under Governance Information (CGR). The document length is 3775 characters, which is substantial for a governance policy document. Therefore, the most appropriate classification is Governance Information (CGR).
2025-08-21 Chinese
内部审计制度
Governance Information Classification · 95% confidence The document is titled "北京三元基因药业股份有限公司 内部审计制度" which translates to "Internal Audit System of Beijing Sanyuan Gene Pharmaceutical Co., Ltd." It details the internal audit policies, procedures, responsibilities, and organizational structure within the company. It includes references to the board of directors, audit committee, internal audit department, and their duties related to internal controls, financial reporting, risk management, and compliance. The document is a formal internal governance document approved by the board and does not contain financial statements or audit opinions from external auditors. It is not a standalone audit report (AR) in the sense of an external audit report, nor is it an annual report (10-K) or interim report (IR). It is also not a regulatory filing or announcement but a governance-related document describing internal audit rules and procedures. Therefore, the best fitting category is Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length (9182 characters) and detailed content support this classification with high confidence.
2025-08-21 Chinese
独立董事工作制度
Governance Information Classification · 100% confidence The document is titled '北京三元基因药业股份有限公司 独立董事工作制度' which translates to 'Beijing Sanyuan Gene Pharmaceutical Co., Ltd. Independent Director Work System'. It details the rules, duties, nomination, election, and working conditions of independent directors, including references to relevant laws, regulations, and governance practices. It is a governance-related document outlining internal rules and procedures for board members, specifically independent directors. There is no financial data, no audit report, no earnings information, no voting results, no capital changes, no legal proceedings, no merger or acquisition details, and no announcement of a report publication. The content fits the definition of Governance Information (CGR) as it details the company's internal rules, board structure, and governance practices related to independent directors.
2025-08-21 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.